Oxford Asset Management’s Forte Biosciences FBRX Stock Holding History

Oxford Asset Management’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-503	Closed	-$2.05M	–	1786
2019 Q1	$2.05M	Buy	503 +94	+23%	+$363K	0.04%	566
2018 Q4	$1.26M	Buy	+409	New	+$1.76M	0.03%	738

Other funds holding FBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Oxford Asset Management's FBRX Position: Q2 2019 in Review

Oxford Asset Management sold out of Forte Biosciences (FBRX) in Q2 2019, closing a stake of 503 shares — an estimated $2.05M sold.

Oxford Asset Management first reported a position in FBRX in Q4 2018 and held it in 2 quarters. The position peaked at $2.05M in Q1 2019. 74 funds tracked by Wall St. Rank hold FBRX as of Q2 2019.

Oxford Asset Management reported no remaining Forte Biosciences position as of Q2 2019 after selling out during the quarter.
Oxford Asset Management sold 503 Forte Biosciences shares in Q2 2019, an estimated $2.05M.
Oxford Asset Management first reported a position in Forte Biosciences in Q4 2018 and held it in 2 quarters.
Oxford Asset Management's Forte Biosciences position peaked at $2.05M in Q1 2019.
74 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2019.

Based on Oxford Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.